How did CSBR's recent EPS compare to expectations?
The most recent EPS for Champions Oncology Inc is $-0.02, not beating expectations of $0.09.
How did Champions Oncology Inc CSBR's revenue perform in the last quarter?
Champions Oncology Inc revenue for the last quarter is $-0.02
What is the revenue estimate for Champions Oncology Inc?
According to 3 of Wall street analyst, the revenue estimate of Champions Oncology Inc range from $17.44M to $16.28M
What's the earning quality score for Champions Oncology Inc?
Champions Oncology Inc has a earning quality score of B+/48.27046. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Champions Oncology Inc report earnings?
Champions Oncology Inc next earnings report is expected in 2026-06-10
What are Champions Oncology Inc's expected earnings?
Champions Oncology Inc expected earnings is $16.94M, according to wall-street analysts.
Did Champions Oncology Inc beat earnings expectations?
Champions Oncology Inc recent earnings of $16.55M does not beat expectations.
Key Stats
Prev.Close
$5.86
Open
$6.01
Day's Range
$5.8 - $6.08
52 week range
$5.5 - $9.97
Volume
3.2K
Avg.Volume
7.0K
EPS (TTM)
0.17
Dividend yield
--
Market Cap
$82.7M
What is CSBR?
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.